1.93
+0.04(+2.12%)
Currency In USD
Address
4149 Liberty Canyon Road
Agoura Hills, CA 91301
United States of America
Phone
805-730-0360
Website
Sector
Healthcare
Industry
Biotechnology
Employees
135
First IPO Date
May 04, 2023
| Name | Title | Pay | Year Born |
| Ms. Mina Kim J.D. | Chief Executive Officer & Director | 0 | 1974 |
| Ms. Patricia A. Turney | Chief Technical Operations Officer | 0 | 1967 |
| Ms. Kelly Chow | Chief People Officer | 0 | N/A |
| Mr. K. Amar Murugan J.D. | Chief Legal Officer | 0 | 1975 |
| Mr. Kenneth A. Lock | Chief Commercial Officer | 0 | 1974 |
| Ms. Suzy Buckhalter CPA | Senior Director of Finance & Accounting | 0 | N/A |
| Mr. Tyler Marciniak | Head of Investor Relations & Communications | 0 | N/A |
| Dr. Shephard Mpofu M.D. | Chief Medical Officer | 0 | N/A |
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.